Literature DB >> 16105892

Radiation dose to family members of hyperthyroidism and thyroid cancer patients treated with 131I.

G S Pant1, S K Sharma, C S Bal, Rakesh Kumar, G K Rath.   

Abstract

The thermoluminescence dosemeter (TLD) was used for measuring radiation dose to family members of thyrotoxicosis and thyroid cancer patients treated with (131)I using CaSO(4):Dy discs. There were 45 family members of thyrotoxicosis patients, who were divided into two groups with 22 in the first and 23 in the second group. Radiation safety instructions were the same for both the groups except in the second group where the patients were advised to use a separate bed at home for the first 3 d of dose administration. An activity ranging from 185 to 500 MBq was administered to these patients. The whole-body dose to family members ranged from 0.4 to 2.4 mSv (mean 1.1 mSv) in the first group and 0-1.9 mSv (mean 0.6 mSv) in the second group. A total of 297 family members of thyroid cancer patients were studied for whole-body dose estimation. An activity ranging from 0.925 to 7.4 GBq was administered to the thyroid cancer patients. The family members were divided into three groups depending upon the mode of transport and facilities available at home to avoid close proximity with the patient. Group A with 25 family members received a dose ranging from 0 to 0.9 mSv (mean 0.4 mSv), group B with 96 family members received a dose ranging from 0 to 8.5 mSv (mean 0.8 mSv) and group C with 176 family members received a dose ranging from 0 to 5.0 mSv (mean 0.8 mSv). The thyroid monitoring was also done in 103 family members who attended the patients in isolation wards for >2 d. Thyroid dose in them ranged from 0 to 2.5 mGy (mean 0.1 mGy).

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16105892     DOI: 10.1093/rpd/nci337

Source DB:  PubMed          Journal:  Radiat Prot Dosimetry        ISSN: 0144-8420            Impact factor:   0.972


  12 in total

1.  Exhalation of ¹³¹I after radioiodine therapy: measurements in exhaled air.

Authors:  Klaus Schomäcker; Ferdinand Sudbrock; Thomas Fischer; Markus Dietlein; Carsten Kobe; Mark Gaidouk; Harald Schicha
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-08-17       Impact factor: 9.236

2.  Re: Radiation exposure levels in family members of Omani patients with thyrotoxicosis treated with radioiodine (I-131) as outpatients.

Authors:  Ramamoorthy Ravichandran; Amal Al-Saadi
Journal:  Sultan Qaboos Univ Med J       Date:  2010-04-17

3.  Radiation exposure levels in family members of omani patients with thyrotoxicosis treated with radioiodine (I) as outpatients.

Authors:  Ibtisaam Al-Maskery; Haddia Bererhi
Journal:  Sultan Qaboos Univ Med J       Date:  2009-06-30

4.  Estimation of the Release Time from Isolation for Patients with Differentiated Thyroid Cancer Treated with High-dose I-131.

Authors:  Jai Hyuen Lee; Seok Gun Park
Journal:  Nucl Med Mol Imaging       Date:  2010-10-22

5.  Behavior and awareness of thyroid cancer patients in Korea having non-hospitalized low-dose radioiodine treatment with regard to radiation safety.

Authors:  Seog Gyun Kim; Jin Chul Paeng; Jae Seon Eo; Hye Kyung Shim; Keon Wook Kang; June-Key Chung; Myung Chul Lee; Dong Soo Lee
Journal:  Nucl Med Mol Imaging       Date:  2010-11-03

6.  Interventional therapy for human breast cancer in nude mice with 131I gelatin microspheres (¹³¹I-GMSs) following intratumoral injection.

Authors:  Chuan-Chao Li; Jun-Lin Chi; Yu Ma; Jian-Hong Li; Chuan-Qin Xia; Lin Li; Zhuo Chen; Xiao-Li Chen
Journal:  Radiat Oncol       Date:  2014-06-23       Impact factor: 3.481

7.  First-day iodine kinetics is useful for individualizing radiation safety precautions for thyroid carcinoma patients.

Authors:  Mikko Tenhunen; Saija Lehtonen; Jorma Heikkonen; Päivi Halonen; Hanna Mäenpää
Journal:  Nucl Med Commun       Date:  2013-12       Impact factor: 1.690

8.  131I thyroid activity and committed dose assessment among family members of patients treated with radioactive iodine.

Authors:  K Brudecki; A Kluczewska-Gałka; P Zagrodzki; B Jarząb; K Gorzkiewicz; T Mróz
Journal:  Radiat Environ Biophys       Date:  2020-06-20       Impact factor: 1.925

9.  Radiation Levels from Toilets Used By Patients Injected with 99mTc-based Radiopharmaceuticals in Ibadan.

Authors:  John Enyi Ejeh; Tolulope Hadrat Abiodun; Kayode Solomon Adedapo; Yetunde Ajoke Onimode; Olusegun Akinwale Ayeni
Journal:  Mol Imaging Radionucl Ther       Date:  2014-06-05

10.  Radionuclide therapy services in an era of COVID-19: the radiation protection challenges, opportunities and considerations.

Authors:  Richard Meades; Gopinath Gnanasegaran; Daniel McCool
Journal:  Nucl Med Commun       Date:  2021-01       Impact factor: 1.698

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.